| Drug Type AAV based gene therapy | 
| Synonyms Adeno-associated viral vector serotype 9 encoding a codon-optimized human ceroid neuronal lipofuscinosis type 7 (CLN7) transgene | 
| Target | 
| Action modulators | 
| Mechanism MFSD8 modulators(Major facilitator superfamily domain-containing protein 8 modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| RegulationOrphan Drug (United States) | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neuronal Ceroid-Lipofuscinoses | Preclinical | United States  | 29 Oct 2024 | 





